Interim or Fractional Chief Medical Officer/Chief Business Officer Network
Many biopharmaceutical companies, especially the emerging or early-stage companies, have a need to access seasoned Chief Medical Officer (CMO) and Chief Business Officer (CBO) executives. Access to this talent in the initial definition of a development program offers numerous benefits, including alignment with the expectations of a larger pharmaceutical partner and the avoidance of costly and time-consuming delays in program execution.
Many of these companies don't have an immediate need to hire a dedicated, full-time CMO or CBO. To that end, we have assembled an aggregate of very senior and capable industry executives that can be accessed by biopharma companies, especially emerging and early-stage companies, in a way that best works for them - whether it's a day a month, a day each week or on a dedicated basis but for some specifically defined period of time. This model is intended to allow a company to scale its use of the function (and the associated expense) as best fits its development. The company isn't burdened by its commitment to a highly salaried employee, doesn't have to pay recruiter fees or deal with large stock-option allocations. Moreover, the talent, with expertise across a range of therapeutic areas, drug development stages and therapeutic technologies, is at an experience level that most companies would likely be unable to attract regardless.
Many biopharmaceutical companies, especially the emerging or early-stage companies, have a need to access seasoned Chief Medical Officer (CMO) and Chief Business Officer (CBO) executives. Access to this talent in the initial definition of a development program offers numerous benefits, including alignment with the expectations of a larger pharmaceutical partner and the avoidance of costly and time-consuming delays in program execution.
Many of these companies don't have an immediate need to hire a dedicated, full-time CMO or CBO. To that end, we have assembled an aggregate of very senior and capable industry executives that can be accessed by biopharma companies, especially emerging and early-stage companies, in a way that best works for them - whether it's a day a month, a day each week or on a dedicated basis but for some specifically defined period of time. This model is intended to allow a company to scale its use of the function (and the associated expense) as best fits its development. The company isn't burdened by its commitment to a highly salaried employee, doesn't have to pay recruiter fees or deal with large stock-option allocations. Moreover, the talent, with expertise across a range of therapeutic areas, drug development stages and therapeutic technologies, is at an experience level that most companies would likely be unable to attract regardless.